{"groups":[{"description":"Patients in the durvalumab (MEDI4736) monotherapy group were to receive durvalumab 10 mg/kg Q2W via intravenous infusion for up to 12 months.","id":"FG000","title":"Durvalumab (MEDI4736)"},{"description":"Patients in the placebo group were to receive matching placebo for intravenous infusion Q2W for up to 12 months.","id":"FG001","title":"Placebo"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"30"},{"groupId":"FG001","numSubjects":"16"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"3"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"260"},{"groupId":"FG001","numSubjects":"149"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Missing Termination Reason"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"476"},{"groupId":"FG001","numSubjects":"237"}],"comment":"Randomized","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"476"},{"groupId":"FG001","numSubjects":"237"}],"type":"Full Analysis Set (FAS)"},{"achievements":[{"groupId":"FG000","numSubjects":"473"},{"groupId":"FG001","numSubjects":"236"}],"type":"Received Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"475"},{"groupId":"FG001","numSubjects":"234"}],"type":"Safety Analysis Set"},{"achievements":[{"groupId":"FG000","numSubjects":"232"},{"groupId":"FG001","numSubjects":"82"}],"type":"Completed 12 Months of Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"178"},{"groupId":"FG001","numSubjects":"68"}],"comment":"Ongoing study at final DCO (study complete)","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"298"},{"groupId":"FG001","numSubjects":"169"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Eligible patients with locally advanced, unresectable Stage III non-small cell lung cancer were randomized in a 2:1 ratio to receive either durvalumab (MEDI4736) 10 milligrams (mg) / kilogram (kg) every 2 weeks (Q2W) or placebo.","recruitmentDetails":"Patients were randomized between 09 May 2014 and 22 Apr 2016 in 235 study centers across 26 countries. Data cut-off (DCO) date for analysis of progression-free survival (PFS) and PFS rates at 12 and 18 months: 13 Feb 2017; DCO date for analysis of overall survival (OS) and all other secondary outcome measures: 22 Mar 2018; DCO date for completion of long-term survival: 11 Jan 2021."}